Table 1.
Phototherapy and photochemotherapy in pediatrics.
| Study and year of publication | # of ptes | Treatment | Age (yr) | Mean # of treatments | Mean cumulative dose (mJ/cm2) | Max dose per Tx (mJ/cm2) | Result |
|---|---|---|---|---|---|---|---|
| Jain et al31 | 18 | NB-UVB + mineral oil vs. NB-UVB alone | Range 5–14 | NB-UVB + MO 20.56 ± 3.06 NB-UVB alone 23.78 ± 3.14 |
NB-UVB + MO 2,956 ± 1070 NB-UVB alone 4,088 ± 1,236 |
NB-UVB + MO 297 ± 100 NB-UVB alone 395 ± 115 |
End point of the study: clearance (achieved in all patients). Greater improvement in scaling, induration and clearance in pre-treated half (P < 0.05). |
| Menter et al34 | 31 | Goeckerman treatment | Youngest patient 1 yr old (other ages not specified) | 12 | NA | NA | Maximum clearing of over 90% seen in 64% of patients; 80%–90% clearing in 23% of patients |
| Borska et al33 | 26 | Goeckerman treatment | Range 8–17, mean 13 | 12–32, average 19 | NA | NA | |
| Kortuem et al32 | 65 | Goeckerman treatment | Mean 11.6 (range 3 months to 18 yrs) | 20 (range 8–37) | NA | NA | 85% of patients had > than 80% clearance of their psoriatic plaques. |
| Ersoy-Evans et al27 | 30 | UVB | 11 ± 3.6 | 28.8 ± 13.3 | 21,000 ± 15,700 | 820 (200–8,200) | 93.3% of patients (n = 28) had more than 75% improvement |
| Ersoy-Evans et al27 | 7 | PUVA | 15 ± 0.7 | 108 ± 68.5 | 498,800 ± 377,000 | 5,200 ± 2,000 | >75% improvement in 83% of patients (n = 5) |